Osiris Therapeutics is a clinical stage biotechnology company founded to commercialize stem cell products from a readily available and non-controversial source – adult bone marrow.  These stem cells have the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including immune disorders, heart attacks, and arthritis.  Due to Osiris’ early commitment to adult stem cell therapeutics, the Company has developed an extensive patent portfolio to protect this technology worldwide.  Osiris has 40 US and 69 foreign patents that cover all of the important aspects of the business.  The Company has three products entering clinical trials.  The lead product, a treatment for GVHD, has successfully completed phase I and is entering phase II

  Inflabloc Pharmaceutical
www.inflabloc.com

Inflabloc Pharmaceuticals is engaged in the research and development of pharmaceutical treatments for inflammatory disorders.  Inflabloc’s current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company’s lead product line is a proprietary DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn’s disease later this year.  IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1004 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.

  Prolexys Pharmaceuticals
www.prolexys.com

Prolexys Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel pharmaceuticals for human use. The Company uses a technology called proteomics, in which an understanding of protein interactions enhances the drug discovery process. Prolexys employs a novel and proprietary set of proteomic technologies that give the company a particular advantage in target identification, an early step in the drug discovery process. The Company has utilized these technologies to discover several series of novel chemicals with promise for treating certain types of cancer and cardiovascular disease. In addition, the Company has created a large proteomic database that is being marketed to larger pharmaceutical research organizations.

  Healagenics
www.healagenics.com

Healagenics is a health-care technology firm focused on the wound-care market. Founded in 2002, the Company has an exclusive (US & Europe) license to certain proprietary technology from Medigenes (a private Korean biotechnology and diagnostics company) that had shown preliminary, but very encouraging clinical data when used to treat approximately 100 patients presenting with a broad spectrum of wounds, that included pressure and diabetic ulcers and open, chemical, radiation and burn wounds.